Lindenberg, M., Kopp, S. and Dressman, J.B. (2004) Classification of Orally Administered Drugs on the World Health Organization Model List of Essential Medicines According to the Biopharmaceutics Classification System. European Journal of Pharmaceutics and Biopharmaceutics, 58, 265-278.
https://doi.org/10.1016/j.ejpb.2004.03.001

has been cited by the following article:

• TITLE: Assessment of Histopathological and Blood Biochemical Profiles in Dairy Cattle Treated with an Experimental Intramuscular Fasciolicide

  AUTHORS: Froylán Ibarra-Velarde, Rosa Arias-García, Yolanda Vera-Montenegro, Miguel Flores-Ramos, Gerardo Leyva-Gómez, Alicia Hernández-Campos

  KEYWORDS: Fasciola Hepatica, Triclabendazole, Fosfatriclaben, Adverse Drug Reaction

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.16 No.10, October 14, 2025

  ABSTRACT: The aim of this work was to determine whether intramuscular administration of injectable fasciolicide fosfatriclaben, in a single dose at 6 mg/kg in dairy cattle, produces adverse reactions manifested through blood biochemical and histopathological profiles, especially in organs involved in drug metabolism. For the study, nine out of ten Holstein-Freisian dairy cows were treated, leaving one cow untreated as a control. On days 0, 7, 14, and 28 post-treatment, liver, kidney, and injection site samples were taken for histopathology, as well as blood samples for biochemical analysis. The results showed no histopathological changes, and the analyte values in biochemical tests remained within the reference range, suggesting the compound has a favorable safety profile.